The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation. Authorized by Congress in the FDA Reauthorization Act of 2017, the designation provides certain incentives for industry to develop generics for drugs lacking competition. FDA Commissioner Scott Gottlieb, M.D., said the agency also will advance additional policies over the next year to promote generic competition. “This will include the publication of a series of guidances to address regulatory and scientific challenges that make it generally more difficult to develop complex generics,” he said. “As part of this, we intend to issue draft guidance with recommendations on establishing active ingredient sameness. In addition, we’ll advance the development of new analytical tools and in vitro tests to provide additional accurate, sensitive and reproducible tools to support approval of complex generic drugs.”

Related News Articles

Headline
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights yesterday held a hearing on surging drug prices and…
Headline
Fourteen leading U.S. drug companies from 2016 to 2020 spent $577 billion on stock buybacks and dividends, $56 billion more than they spent on research…
Headline
The Department of Health and Human Services today withdrew requests for proposals on ways individuals could import prescription drugs from other countries…
Headline
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304).    “America’s hospitals and health systems are…
Headline
Retail prices for 260 widely used brand-name prescription drugs last year increased by an average 2.9%, more than twice the general rate of inflation,…
Headline
The Campaign for Sustainable Rx Pricing (CSRxP), of which the AHA is a founding member, today launched new television and digital advertising encouraging…